Sanofi halts Phase 3 trial of riliprubart in rare neurological disorder

Sanofi announced it is ending the Phase 3 study of its antibody drug riliprubart aimed at treating a rare neurological disease.

The decision follows a recommendation from an independent data monitoring committee that the trial was unlikely to demonstrate sufficient efficacy.

Sanofi said it will now assess the future of the program, including whether to pursue other indications or discontinue development.

The move underscores the challenges of advancing therapies for rare neurodegenerative conditions and may affect the company’s pipeline expectations.